To explore this further, we analysed an additional 12 patients with metastatic prostate cancer, five of whom had paired primary tissue samples, and an additional 19 patients with localized disease, performing tagged-amplicon deep sequencing (TAm-Seq26) on all 38 patients to interrogate entire exonic regions of TP53. This combined cohort of 19 metastatic and 19 localized patients comprised 91 samples, including 48 metastatic tissue/blood/plasma samples and 43 primary tissue/blood/plasma samples. The gene discussed is TP53; the disease is metastatic prostate carcinoma.